Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

G3 Completes GLOBAL Study Patient Enrollment

Published: Thursday, February 13, 2014
Last Updated: Monday, February 17, 2014
Bookmark and Share
Pilot data of single largest prospective pan-omic study to identify key biomarkers and central therapeutic targets for cardiovascular diseases.

Global Genomics Group (G3) announce that it has completed enrollment of the 5,000-patient discovery cohort of its GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) clinical study. Pilot data for the first cohort of patients are expected later this year.

The GLOBAL study, designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis, enrolled 5,000 patients in the discovery group, with approximately 2,500 patients in the control group and approximately 2,500 patients in the case group. Precision phenotyping is conducted with cardiovascular computed tomography (CT), including calcium scoring and CT angiography, an advanced, non-invasive imaging technology. A pan-omic analysis that includes whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics and lipidomics, will be conducted for every patient. The data will be analyzed with systems biology driven bioinformatics.

"The strong interest and support from the medical community has allowed us to rapidly enroll patients at many of the top centers worldwide, and we are well ahead of our original schedule," said Bradley Brown, co-founder and vice president of clinical affairs of G3. "This is an important milestone for G3 as well as for our collaborating researchers and participating patients. The GLOBAL study will allow us to gain important insights about the development of cardiovascular disease and to identify new disease biomarkers and therapeutic targets. We anticipate that the pilot data set will be available later this year."

The GLOBAL study is enrolling patients at 48 institutions in 9 countries and across three continents. The investigators anticipate enrolling an additional 2,000 patients in the validation cohort, with approximately 1,000 patients in the disease group and 1,000 in the control group.

Stephen Bloom, M.D., of Midwest Heart & Vascular Specialists, Kansas City, Mo., a principal investigator of the study, said, "Cardiovascular disease remains the leading cause of death worldwide, and the biological pathways leading to atherosclerosis — the primary reason for heart attacks and stroke — remain largely unknown. The GLOBAL study is the most ambitious study ever undertaken to investigate the root cause of this complex disease and may not only provide us with new biomarkers and drug targets, but it will also provide us with a platform for early screening, continued monitoring of risk, prevention and early intervention."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

G3, Caprion Partner on Global Cardiovascular Disease Biomarker Study
Caprion to identify blood-based protein markers for study.
Wednesday, February 26, 2014
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Cell Metabolism Linked to Spread of Cancer
Scientists discover macrophage metabolism can be attuned to prevent the spread of cancer.
Fatty Liver Disease Linked to Type 2 Diabetes
Recent study identifies factors causing insulin to misbehave in non-alcoholic fatty liver disease.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Lab-on-a-Chip Detects Effects of Poison
A fast and efficient mixer has been developed for testing the effect of toxic substances faster by using a new lab-on-a-chip.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Targeting Cardiovascular Disease Risk Factors May be Important Across a Lifetime
The study suggests efforts to prevent risk factors should extend to those older than 65.
Beige Fat Formation Linked to Anti-diabetic Effect
Researchers at UTSW have found that the protein connexin 43 forms cell-to-cell communication channels on the surface of emerging beige fat cells that amplify the signals from those few nerve fibers.
Adipose Tissue Secretes Factors That Activate Metabolism
Study finds brown adipose tissue secretes signalling factors that activates metabolism of fat and carbohydrates.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos